Immunotherapy in Ovarian Cancer

Cancer research · Ovarian cancer · TP53 · ERBB2

Immunotherapy represents a promising therapeutic approach for ovarian cancer, but further evidence from large controlled studies is required to establish its efficacy.

Despite advances in surgery and chemotherapy, ovarian cancer remains one of the most lethal malignancies. Hence, the implementation of novel treatment approaches is required to improve the outcomes of the disease. Immunotherapy has been proven to be effective in many tumors and has already been incorporated into clinical practice. In this review, we describe key strategies in immunotherapy of ovarian cancer and summarize data from clinical studies assessing immunological prospects which could improve ovarian cancer treatment approaches in the future. The most notable current strategies include checkpoint blockade agents, the use of vaccines, adoptive cell transfer, as well as various combinations of these methods. While several of these options are promising, large controlled randomized studies are still needed to implement new immunotherapeutic options into clinical practice.

Ovarian cancer is the most lethal gynecologic malignancy, with high recurrence rates and limited therapeutic options. Immunotherapy offers a novel, potentially effective strategy that could improve survival and reduce toxicity compared to standard chemotherapy.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals